Sugi Predict

Sugi Predict / Compounds / SCHEMBL2958649

SCHEMBL2958649

SCHEMBL2958649

CC(C)(C)OC(=O)N1CC[C@@H](O[Si](C)(C)C(C)(C)C)[C@@]1(C)CO

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NR1H2 P55055 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CHRM2 P08172 1/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ DDB1 Q16531 1/20 0.31
▸ CRBN Q96SW2 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.30
▸ GPR119 Q8TDV5 1/20 0.30
▸ EPHX1 P07099 1/20 0.30
▸ FAAH O00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371165 1.00 RECQL (0.33) RECQLUSP2SMN1; SMN2NR1H2HPGD
SCHEMBL4371444 1.00 RECQL (0.33) RECQLUSP2SMN1; SMN2NR1H2HPGD
SCHEMBL6026102 1.00 RECQL (0.33) RECQLUSP2SMN1; SMN2NR1H2HPGD
SCHEMBL4370444 1.00 RECQL (0.33) RECQLUSP2SMN1; SMN2NR1H2HPGD
SCHEMBL2966020 0.86 PPM1D (0.33) —
SCHEMBL4370217 0.86 PPM1D (0.33) —
SCHEMBL6052834 0.86 PPM1D (0.33) —
SCHEMBL15512775 0.81 SMN1; SMN2 (0.33) RECQLUSP2SMN1; SMN2HPGDCHRM2
SCHEMBL143218 0.81 SMN1; SMN2 (0.33) RECQLUSP2SMN1; SMN2HPGDCHRM2
SCHEMBL4370286 0.79 RECQL (0.32) RECQLUSP2SMN1; SMN2HPGDCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1261793-A Sertraline salts and sustained release dosage forms of sertraline PFIZER (US) 2000-08-02 — — CN claimed
US-7772267-B2 or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-10 — — US disclosed
US-7772438-B2 Process of making sertraline form I HETERO DRUGS LIMITED (IN) 2010-08-10 — — US disclosed
US-7772267-B2 or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-10 — — US disclosed
US-7772437-B2 Process of making sertraline form II HETERO DRUGS LIMITED (IN) 2010-08-10 — — US disclosed
CN-101484411-A New process for the preparation of salts SANDOZ AG (CH) 2009-07-15 — — CN disclosed
US-20090177010-A1 PROCESS OF MAKING SERTRALINE FORM I HETERO DRUGS LIMITED (IN) 2009-07-09 — — US disclosed
US-20090177009-A1 PROCESS OF MAKING SERTRALINE FORM II HETERO DRUGS LIMITED (IN) 2009-07-09 — — US disclosed
CN-100494162-C Method for separating non-geometric proportion cis-sertraline hydrochloride mixture ZHEJIANG NEW DANKONG PHARMACEU (CN) 2009-06-03 — — CN disclosed
US-7518019-B2 Processes for preparing sertraline hydrochloride crystalline forms HETERO DRUGS LIMITED (IN) 2009-04-14 — — US disclosed
US-6495721-B1 MAKING SERTRALINE HYDROCHLORIDE FORM II FROM SERTRALINE BASE OR SERTRALINE MANDELATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2002-12-17 — — US disclosed
US-20020183555-A1 Sertraline hydrochloride form II and methods for the preparation thereof SCHWARTZ EDUARD (IL) 2002-12-05 — — US disclosed
EP-1133459-A1 SERTRALINE HYDROCHLORIDE FORM V TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2001-09-19 — — EP disclosed
WO-2000032551-A9 SERTRALINE HYDROCHLORIDE POLYMORPHS TEVA PHARMA (IL) 2001-07-19 — — WO disclosed
CN-1285819-A Novel method for producing ketimines PFIZER PROD INC (US) 2001-02-28 — — CN disclosed
CN-1277188-A Process for producing sherchulin with chiral naphthane one PFIZER PROD INC (US) 2000-12-20 — — CN disclosed
CN-1261793-A Sertraline salts and sustained release dosage forms of sertraline PFIZER (US) 2000-08-02 — — CN disclosed
WO-2000032551-A1 SERTRALINE HYDROCHLORIDE POLYMORPHS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2000-06-08 — — WO disclosed
EP-0999830-A1 SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE PFIZER INC. (US) 2000-05-17 — — EP disclosed
WO-1999001121-A1 SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE PFIZER INC. (US) 1999-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090177010-A1 PROCESS OF MAKING SERTRALINE FORM I HTR5A, HTR2A, HTR2C RECQL 2966/4885USP2 3571/4885SMN1; SMN2 1962/4885
US-20090177009-A1 PROCESS OF MAKING SERTRALINE FORM II HTR5A, HTR2A, HTR2C RECQL 3038/4885USP2 3018/4885SMN1; SMN2 1935/4885
US-20020183555-A1 Sertraline hydrochloride form II and methods for the preparation thereof HTR5A, SLC6A4, HTR2C RECQL 895/4885USP2 3318/4885SMN1; SMN2 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.